![Pharmaceutics | Free Full-Text | Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases Pharmaceutics | Free Full-Text | Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01746/article_deploy/html/images/pharmaceutics-15-01746-g002.png?1686909299)
Pharmaceutics | Free Full-Text | Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases
![Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/aef87f29-5fed-44e8-9b00-dcc28e6c5361/cxo12507-fig-0001-m.jpg)
Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library
![CAS No : 155206-00-1| Product Name : Bimatoprost - API| Chemical Name : Bimatoprost | Pharmaffiliates CAS No : 155206-00-1| Product Name : Bimatoprost - API| Chemical Name : Bimatoprost | Pharmaffiliates](https://www.pharmaffiliates.com/pimages/PA0272000.jpg)
CAS No : 155206-00-1| Product Name : Bimatoprost - API| Chemical Name : Bimatoprost | Pharmaffiliates
![Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients](https://mma.prnewswire.com/media/222796/allergan_plc_logo.jpg?p=facebook)
Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients
![Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage | Molecular Pharmaceutics Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.6b00445/asset/images/large/mp-2016-00445e_0009.jpeg)
Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage | Molecular Pharmaceutics
![Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d8032578-87dc-4ad6-80f8-ce0b9655a2b7/cxo12507-fig-0004-m.jpg)
Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface - Bitton - 2017 - Clinical and Experimental Optometry - Wiley Online Library
Public Assessment Report Scientific discussion Bimato-Vision 0.1 mg/ml, eye drops, solution (bimatoprost) NL/H/3025/001/DC Date
![Medical anti‐glaucoma therapy: Beyond the drop - Miller - 2021 - Veterinary Ophthalmology - Wiley Online Library Medical anti‐glaucoma therapy: Beyond the drop - Miller - 2021 - Veterinary Ophthalmology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/90aee72f-b952-4da8-9039-1124023afc93/vop.v24.s1.cover.jpg?trick=1692474192268)
Medical anti‐glaucoma therapy: Beyond the drop - Miller - 2021 - Veterinary Ophthalmology - Wiley Online Library
![Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats | Communications Biology Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats | Communications Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs42003-022-04134-w/MediaObjects/42003_2022_4134_Fig1_HTML.png)
Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats | Communications Biology
![In situ gel containing Bimatoprost solid lipid nanoparticles for ocular delivery: In-vitro and ex-vivo evaluation - ScienceDirect In situ gel containing Bimatoprost solid lipid nanoparticles for ocular delivery: In-vitro and ex-vivo evaluation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1773224719311396-fx1.jpg)
In situ gel containing Bimatoprost solid lipid nanoparticles for ocular delivery: In-vitro and ex-vivo evaluation - ScienceDirect
![Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment - ScienceDirect Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S154201242300054X-gr1.jpg)
Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment - ScienceDirect
Abstracts from the 2015 European Association for Vision and Eye Research Conference: Acta Ophthalmologica: Vol 93, No S255
![An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma | Eye An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma | Eye](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41433-021-01766-w/MediaObjects/41433_2021_1766_Fig1_HTML.png)